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Objective: To describe themethods used in a rapid review of the literature and to present
the main epidemiological parameters that describe the transmission of SARS-Cov-2 and
the illness caused by this virus, coronavirus disease 2019 (COVID-19).
Methods: This is a methodological protocol that enabled a rapid review of COVID-19
epidemiological parameters.
Findings: The protocol consisted of the following steps: definition of scope; eligibility
criteria; information sources; search strategies; selection of studies; and data extraction.
Four reviewers and three supervisors conducted this review in 40 days. Of the 1,266
studies found, 65 were included, mostly observational and descriptive in content,
indicating relative homogeneity as to the quality of the evidence. The variation in the
basic reproduction number, between 0.48 and 14.8; and themedian of the hospitalization
period, between 7.5 and 20.5 days stand out as key findings.
Conclusion: We identified and synthesized 10 epidemiological parameters that may
support predictive models and other rapid reviews to inform modeling of this and other
future public health emergencies.
Keywords: coronavirus infections, review, parameters, methods, models, statistical
INTRODUCTION
Public Health is confronted with the challenge of protecting poulations from emerging and
reemerging diseases. Among the viruses capable of causing pandemics, special prominence is given
to the family Coronaviridae (1–3). These viruses are responsible for three recent major epidemics:
in 2009, the Severe Acute Respiratory Syndrome (SARS), caused by the Severe Acute Respiratory
Syndrome Coronavirus (SARS-CoV); in 2012, the Middle East Respiratory Syndrome, caused by
the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (4); and, in 2019, the Corona
Virus Disease−19 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) (5). However, SARS-CoV-2 has peculiar clinical and epidemiological characteristics
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when compared with SARS-CoV, MERS-CoV, or others of
the same family. These characteristics are reflected in the
exponentially increasing numbers of COVID-19-related
deaths (6).
The current epidemic goes back to December 31, 2019, when
a pneumonia outbreak was reported in Wuhan, China, with 27
cases that were later identified as COVID-19 cases (7). In the
following months, the epidemic evolved from a local problem
to a pandemic with catastrophic consequences. As of August
13, ∼20,5 million cases and 744,500 deaths had been reported
to the World Health Organization (WHO), in all age ranges
and nearly all continents—except Antarctica. The Americas are
currently regarded as the epicenter of the pandemic, where 53.6%
of the total recorded cases have been reported−54.7% of the cases
recorded within the last 24 h in the world. The United States and
Brazil are particularly affected. These countries have 5,094,500
cases (163,340 deaths) and 3,109,630 cases (103,026 deaths),
respectively (8).
Understanding the parameters that influence the course of an
epidemic is key for health-related decision-making and allows
for planning of strategies to mitigate and control diseases,
as well as provision of care to those infected and sick. The
high transmissibility and virulence of SARS-CoV-2, lead to a
significant rate of severe and critical cases requiring specialized
care and intensive care beds, creates the need for predictive
models capable of estimating health care demands and support
decision-making (9–11).
Mathematical models are simplifications of complex
processes involved in disease dynamics, which can lead to
different results based on the method, assumptions and
parameters adopted (12). To minimize uncertainties, parameters
feeding the model must be valid, accurate, generalizable, and
reliable, as well as adaptable in population-based terms. In
an emergent situation these models may contain a series of
uncertainties, due to the incipient availability of epidemiological
characteristics (10, 11). This requires constant review of
parameters as new information arises, as well as an ongoing
literature review.
TABLE 1 | Description of identified epidemiological parameters of COVID-19.
Parameters Description
Basic reproduction number (R0) The mean number of new infections arising from one infected person in a totally susceptible population (13).
Serial interval Time between onset of symptoms in a primary case (infector) and onset of symptoms in a secondary case
(infectee) (14).
Incubation period Time between infection and onset of disease (15).
Transmissibility period Time during which a person infected with SARS-CoV-2 transmits the virus to other people.
Proportion of detected cases Proportion of cases identified as infected with SARS-CoV-2 among all cases tested.
Proportion of critical cases among hospitalized patients Proportion of critical cases of COVID-19 among all hospitalized patients.
Proportion of deaths among critical cases Proportion of deaths from COVID-19 among all critical cases of the disease.
Mean or median length of hospital stay Time in days (mean or median) of hospital stay among COVID-19 cases.
Mean or median time between admission to hospital and
onset of ARDSa
Time in days (mean or median) of hospital stay among COVID-19 cases before onset of ARDSa.
Length of hospital stay in wards before admission at ICUb Time in days (mean or median) of hospital stay in wards among COVID-19 cases who required ICUb.
aAcute respiratory distress syndrome.
b Intensive care unit.
The COVID-19 emergency has prompted researchers to
work toward describing different aspects of disease transmission
and evolution. As a result, a significant number of scientific
publications are being released daily, and theMEDLINE database
alone already had 16,000 publications (keyword “COVID-19”) as
of May 26, 2020—when this study was performed. Information
from these publications can help decision-makers develop
policies throughout the course of the emergency. However, due
to the large number of studies available, identifying the relevant
evidence in due time presents a great challenge and requires that
the methods used in traditional literature reviews be adapted.
To support evidence-based decision-making using predictive
models for the COVID-19 public health emergency, while the
epidemic was establishing in Brazil, a rapid literature review
method was proposed with the view to identify and describe
clinical and epidemiological parameters relative to infection by
SARS-CoV-2 and the illness caused by this virus, coronavirus
disease 2019 (COVID-19). This article, therefore, aims to
describe the methods employed in this rapid literature review
and present the main epidemiological parameters describing
SARS-CoV-2 transmission and the COVID-19 disease.
MATERIALS AND METHODS
A methodological proposal for rapid review of epidemiological
parameters and their application in the context of the current
SARS-CoV-2 pandemic emergency.
Proposed Methodology
A rapid literature review, with the aim to identify clinical and
epidemiological parameters to support mathematical models of
COVID-19 transmission and disease. The proposed rapid review
method developed by the authors includes the following steps:
research scope definition; eligibility criteria; information sources;
database search strategies; study selection; and data extraction.
For method construction, we met with the group of modelers to
identify the required parameters. The parameters defined for the
search and their descriptions are provided in Table 1.
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TABLE 2 | Methodological proposal for quick literature review: identification of epidemiological parameters.
Steps Description
Search scope It should be structured as follows: definition of the population to be studied; choice of epidemiological parameters; organizing groups of
parameters according to similarity (e.g., types of studies that generate them).
Eligibility criteria For a quick and reliable selection, only include studies published as from the date of the first outbreak of the disease in the world;
presenting at least one of the parameters assessed in the abstract; original investigations, literature reviews; published in English or in
other languages of the group domain; including studies published in other languages, but with the abstract in the languages of the domain
that allow clear identification of any parameters of interest. It is suggested for reviewers to exclude: studies from preprint databases that
analyzed primary data and have not been submitted to ethical evaluation; opinion articles; epidemiological bulletins with overlapping data
of the same place, and studies that do not allow a reliable translation.
Sources of information Literature search should be divided into two phases: the first should search at least two international databases, and the second should
track the lists of references of studies identified in the first stage.
Search in the
databases
The search syntax must represent the problem to be investigated, its primary endpoints and the date that best represents the beginning of
the first outbreak in the world. For example: (name of the disease OR name of virus) AND (endpoint 1 OR endpoint 2) AND (start date AND
final date).
Study selection Study selection should comprise the following stages: selection of studies for complete assessing, from evaluation of titles and abstracts
as per eligibility criteria; reading of full texts and new evaluation considering eligibility. Non-matching stages, but with the support of a more
experienced researcher to clarify doubts and organize the process.
Data extraction Data extraction should be guided by means of a structured tool, which allows the objective identification of parameters and a quick




During the preparation stage, the group developed a
methodological protocol to guide construction of the methods
employed in the rapid literature review. The protocol was
composed of six stages, the respective descriptions of which are
provided in Table 2.
Operationalizing the Rapid Literature
Review
The population of interest was composed of people living in
high-risk areas of SARS-CoV-2 infection. The epidemiological
parameters were divided into two groups, for better organization
of the syntax and database search. The first group, referred to as
Group 1, included the following parameters: basic reproduction
number (R0); serial interval; incubation period; transmissibility
period. The second, referred to as Group 2, included the
following parameters: rate of detected cases; rate of critical cases
among all hospitalized patients; rate of deaths among critical
cases; mean or median length of hospital stay; mean or median
time between hospital admission and ARDS (Acute Respiratory
Distress Syndrome) onset; or mean or median length of hospital
stay before ICU (Intensive Care Unit) admission.
To identify Group 1 and Group 2 parameters, we selected
studies indexed in databases: Medical Literature Analysis and
Retrieval System Online (MEDLINE) and Excerpta Medica
dataBASE (EMBASE). For each group of parameters, we
organized search syntaxes on MEDLINE, via PubMed and
on EMBASE, based, respectively, on MeSH (Medical Subject
Headings) and Emtree (Embase Subject Headings) terms.
Searches were performed in two stages, one on March 27, 2020
and the second on April 13, 2020. Additional studies were
obtained frommannualy searches in the references of the selected
articles and reviews.
We organized four search syntaxes based on the group of
parameters and the database. Table 3 shows the search syntaxes
used to identify studies on MEDLINE via PubMED, which were
adapted for EMBASE. Duplicates were removed with the help
of reference management software programs Mendeley Desktop
version 1.19.4 and Covidence.
The eligibility criteria included studies published as of January
1, 2020. We included original research studies, epidemiological
bulletins and literature reviews addressing any of the parameters
of interest, published in English, Spanish or Portuguese. Studies
in other languages were included only when any of the
parameters of interest could be identified in the Abstract
published in English, Spanish or Portuguese. The list of elegibility
criteria is presented in Table 2.
For study selection, the titles and abstracts identified were
classified as per the inclusion and exclusion criteria. Studies
that met the inclusion criteria and none of the exclusion
criteria were selected for full reading and reassessed for
eligibility. Data were extracted based on three spreadsheets
specifically developed for the parameters addressed in
the review.
Data search, inclusion, reading, and extraction were not
conducted in a paired fashion, and each study was reviewed by
an investigator under supervision by a second, more experienced
investigator with an epidemiology background. The supervisor
supported every stage of the review, providing guidance and
answering questions, and that data extraction was entirely
verified by two supervisors.
Epidemiological Parameters
Figure 1 describes the flow of information at different stages of
the review. At first, we found 951 studies using the strategies set
up to identify parameters in Group 1 and 1,206 studies using
the strategies to retrieve parameters in Group 2. After assessing
for duplicates, we were left with 1,266 studies (Group 1: 355
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TABLE 3 | Search syntax: MEDLINE.
MEDLINE/GROUP 1: ((“coronavirus”[MeSH Terms] OR “severe acute respiratory syndrome coronavirus 2”[Supplementary Concept] OR “severe acute respiratory
syndrome coronavirus 2”[All Fields]) OR “COVID-19”[All Fields] OR “COVID-19”[Supplementary Concept] OR “Novel Coronavirus” [All Fields]) AND ((((“basic reproduction
number” [MeSH Terms] OR (“basic” [All Fields] AND “reproduction”[All Fields] AND “number”[All Fields]) OR “basic reproduction number”[All Fields]) OR R0[All Fields] OR
“basic reproductive number”[All Fields] OR (basic[All Fields] AND (“reproduction”[MeSH Terms] OR “reproduction”[All Fields] OR “reproductive”[All Fields]) AND number[All
Fields])) OR (“infectious disease incubation period”[MeSH Terms] OR (“infectious”[All Fields] AND “disease”[All Fields] AND “incubation”[All Fields] AND “period”[All Fields])
OR “infectious disease incubation period”[All Fields])) OR ((“disease transmission, infectious”[MeSH Terms] OR (“disease”[All Fields] AND “transmission”[All Fields] AND
“infectious”[All Fields]) OR “infectious disease transmission”[All Fields] OR (“disease”[All Fields] AND “transmission”[All Fields] AND “infectious”[All Fields]) OR “disease
transmission, infectious”[All Fields]) OR (communicable[All Fields] AND period[All Fields]))) AND (“2020/01/01”[PDAT] : “2020/04/13”[PDAT])
MEDLINE/GROUP 2: ((“coronavirus”[MeSH Terms] OR “severe acute respiratory syndrome coronavirus 2”[Supplementary Concept] OR “severe acute respiratory
syndrome coronavirus 2”[All Fields]) OR “COVID-19”[All Fields] OR “COVID-19”[Supplementary Concept] OR “Novel Coronavirus”[All Fields]) AND
((((((((“Hospitalization”[Mesh] OR “Critical Care”[Mesh]) OR “Intensive Care Units”[Mesh]) OR “Critical Illness”[Mesh]) OR “Mortality”[Mesh]) OR “Hospital Mortality”[Mesh])
OR “Pneumonia, Ventilator-Associated”[Mesh]) OR “Disease Attributes”[Mesh] OR “hospitalized patient*”[All Fields] OR (epidemiological characteristic[All Fields] OR
epidemiological characteristics[All Fields]) OR (clinical characteristic[All Fields] OR clinical characteristics[All Fields]) OR (clinical outcome[All Fields] OR clinical
outcomes[All Fields] OR clinical outcomes,[All Fields]) OR “hospitalization rate”[All Fields] OR (undocumented[All Fields] AND (“infections”[MeSH Terms] OR “infections”[All
Fields] OR “infection”[All Fields])) OR “documented infection”[All Fields]) OR (((((((“Epidemiologic Studies”[Mesh] OR “Clinical Studies as Topic”[Mesh]) OR “Epidemiologic
Study Characteristics”[Mesh]) OR “Decision Support Techniques”[Mesh]) OR “Case Reports”[Publication Type]) OR “Observational Study”[Publication Type]) OR “Cohort
Studies”[Mesh]) OR ((“IEEE Int Conf Automation Sci Eng (CASE)”[Journal] OR “CASE (Phila)”[Journal] OR “case”[All Fields]) AND (“SERIEs (Berl)”[Journal] OR “series”[All
Fields])))) AND (“2020/01/01”[PDAT] : “2020/12/31”[PDAT]) AND (“2020/01/01”[PDAT] : “2020/04/13”[PDAT])
and Group 2: 911), of which 65 were included (Group 1: 37 and
Group 2: 35).
Epidemiological parameters were divided into 3 datasets
according to the groups searched.
Table 4 shows search results by basic reproduction number
(R0) and time-varying reproduction number (Rt)—when
present—in the 19 studies identified (16–18, 20–35). Analyses
relied mostly on data from China, followed by Japan and South
Korea, and were performed between December 2019 and March
2020. The highest R0 identified was 14.8, estimated for the
Diamond Princess cruise-ship during its quarantine in Japan
(22), and the lowest was 0.48 - in South Korea (30). Decreases
in SARS-CoV-2 reproduction numbers have been seen after
restrictive measures were implemented.
Data extracted from studies on incubation and
transmissibility periods and serial interval can be seen in
Table 5. We identified 22 studies (14, 15, 26, 30, 31, 33, 36–
51) of which 19 (14, 15, 26, 30, 33, 36–41, 43, 44, 46–51)
addressed the incubation period, with means ranging
from 3.6 days (48) to 6.7 days (39); one addressed the
transmissibility period [Median: 9.5 days, interquartile
range (IQR) 3.5–13.0] (42); and five (26, 30, 31, 36, 45)
addressed the serial interval, with means ranging from
3.96 (31) to 7.5 days (26). The parameters presented
in the chart were predominantly estimated based on
descriptive observational studies from China, South Korea,
and Singapore.
Table 6 shows results for Group 2 and the rate of detected
cases; rate of critical cases among all hospitalized patients; rate of
deaths among critical cases; mean or median length of hospital
stay; mean or median time between hospital admission and
ARDS onset; or mean or median length of hospital stay before
ICU admission. These parameters were mostly extracted from
studies in China, predominantly with adult and elderly subjects
aged between 41 and 68 years, and males. Of the 35 studies
reviewed (34, 46, 49–79), only three (52, 53, 79) showed the
proportion of cases identified as infected with SARS-CoV-2
among all cases tested (detected cases), and numbers ranged
between 4.45% (79) and 61.8% (53). In the studies, there was
variability in the criteria used to define cases as critical, and
data showed that the proportion of critical COVID-19 cases
among all hospitalized patients ranged between 0.06% (51) and
86.9% (56). Not all studies reported the number of deaths among
critical cases, and when they did (49, 51, 56, 57, 60–62, 65–
67, 70, 73, 75, 77, 78), the rate identified was 1.35% (49) to 78%
(60). The median length of total stay among COVID-19 cases
ranged from aminimum of 7.5 days (cases with a death outcome)
(60) and a maximum of 20.5 days (77). The median length of
outpatient stays prior to ARDS onset ranged between two (66)
and 14 (62) days. The median lenght of outpatients stays prior to
ICU admission was reported in one study as one day (57) and the
mean as 8 days (64).
DISCUSSION
This study presented a proposal of a rapid literature review
method, which identified a set of epidemiological parameters
aiming to support construction of predictive models and
evidence-based decision-making in view of the COVID-19
pandemic. The syntaxes developed and the rapid review
method proposed allowed for identification and synthesizing
of all epidemiological parameters of interest in only 40
days. This required the joint effort of researchers and
adjustments to the method usually recommended for systematic
literature reviews.
Although complex, it is imperative to select good parameters
to support mathematical and epidemiological models that predict
diseases dynamics in different territories, especially emergent and
reemergent epidemics. For COVID-19, the models presented to
date are mostly based on local parameters of early stages of the
epidemic, as well as the viral behavior of other coronaviruses,
such as those causing SARS and MERS outbreaks. Our results
show that it is possible to overcome said difficulties by rapidly
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FIGURE 1 | Flowchart of the selection process of evidence of clinical and epidemiological parameters of COVID-19. a, First group of parameters (syntax group 1); b,
Second group of parameters (syntax group 2); c, articles published as pre-prints; d, article in non-English, Spanish, or Portuguese and the parameter data was not
included in the abstract; e, it was not possible to extract the parameters of interest; f, did not provide data on COVID-19; g, Laboratory studies or other techniques.
and systematically gathering evidence produced with different
methodologies and in different settings, facilitating identification
of parameters that are more suitable to the context and the
purpose of the predictive model, improving quality and accuracy
of results, and potentially helping territories enhance their
COVID-19 preparedness and emergency response.
For all parameters assessed, we found a higher frequency of
studies from China. We believe this was due to fact that COVID-
19-related cases first emerged in China, which favors a higher
number of studies coming from there. Only a few studies were
from Europe, the Americas and regions other than Asia, however,
with the spread of COVID-19 throughout the world, studies
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TABLE 4 | Presentation of parameters: basic reproduction number (R0).
Author, year
[references]
Country Date of study Method: R0a Others












February 2020 Package “earlyR” 2.28 (95%CI: 2.06–2.52) –
Kuniya, 2020 (17) Japan Between January
and February 2020
SEIR Modeld 2.6 (95%CI: 2.4–2.8) –




SEIR Modeld – R according to date: Day 0: 2.4;
day 10: 3.2; day 20: 2.98, etc.
Zhao et al., 2020
(19)
China January 2020 Statistical exponential growth
modele





Stochastic transmission model – Rtb (before and after restriction
measures): 2.35 (95%CI:
1.15–4.77) to 1.05 (95%CI:
0.41–2.39)





SEIR Modeld 3.1 Rtb measured in distinct phases














Next generation matrix (NGM)f in a
totally susceptible population
Maximum Rtb: 11.2 (95%CI:
7.5—16.2) and median Rt: 5.8
(95%CI: 0.6–11.0)
Tang et al., 2020
(24)
China January 2020 SEIR Modeld 6.47 (95%CI: 5.71—7.23) –
Wu et al., 2020 (25) China Between
December 2019
and January 2020
SEIR Modeld 2.68 (95%CI: 2.47–2.86) –
Li et al., 2020 (26) China January 2020 Statistical exponential growth
modele
2.2 (95%CI: 1.4–3.9). –
Zhao et al., 2020
(27)
China January 2020 Exponential growth model by
Poisson in a completely
susceptible population
2.56 (95%CI: 2.49–2.63) –






3.49 (95%CI: 3.42–3.58) After containment measures Rtb:
2.95 (95%CI: 2.86–3.03)
Zhou et al., 2020
(29)
China January 2020 SEIR Modeld 2.8–3.3 –
Ki and Task Force
for 2019-nCoV,
2020 (30)
South Korea Between January
and February 2020
Not informed 0.48 (95%CI: 0.25–0.84) –
Du et al., 2020 (31) China Between January
and February 2020
Exponential growth model based
on public data from Wuhan
1.32 (95%CI: 1.16–1.48) –
Anastassopoulou
et al., 2020 (32)
China Between January
and February 2020
SIDR modelg 2–2.6 Other R0a estimates based on
linear regression varied between
3.2 (95%CI: 2.4–4) and 5.14
(95%CI: 4.25–6.03).
Song et al., 2020
(33)*
China January 2020 Weibull distribution methods,
Gamma
Lognormal,
Weibull distribution methods: 3.74
(95%CI: 3.63–3.87);









Used a method proposed by Cori
et al. (2013)h in R version 3.6.2.
– Maximum Rtb — 03/01/2020:
3.94 (95%CI: 3.32—-4.63);
Minimum Rtb: 08/03/2020: 0.10
(95%CI: 0.08—-0.13)
aR0, basic reproduction number.
bRt, effective basic reproduction number (variable in time).
cReservoir–People transmission network.
dSEIR: Susceptible – Exposed – Infected – Recovered.
eStatistical exponential growth model.
fNGM: next–generation matrix.
gSIDR: Susceptible – Infected – Recovered – Death.
hCori A et al. (2013). doi: 10.1093/aje/kwt133.
*Article in Chinese, only the abstract in English was assessed.
Frontiers in Public Health | www.frontiersin.org 6 December 2020 | Volume 8 | Article 598547
Gallo et al. Clinical-Epidemiological Parameters of COVID-19
TABLE 5 | Presentation of serial interval parameters, incubation period, and transmissibility period.
Author, year
[references]
Country Study date Characteristics of the sample




Linton et al., 2020
(14)
China January 2020 N = 158 cases; predominance





Song et al., 2020
(33)*
China January 2020 No information Mean: 5.01.
(95%CI: 4.31–5.69 days).
– –
Pung et al., 2020
(36)
Singapore February 2020 N = 36 cases; 17 positive cases;
Age [median (IQR)]: 40 (36–51)
years; Female sex: 59%
Median: 4 days
(IQR: 3–6 days).
– Range: 3–8 days
Chan et al., 2020
(37)
China January 2020 N = 6 cases; 5 adults and one
child, Age (mean): 45 years;
Female sex: 50%
Range: 3–6 days – –







N = 181 cases; Age [median









N = 54 cases; Age [mean (lower
and upper limits)]: 38 (1, 67–94)
years; Female sex: 33.3%; 19
cases subsidized the estimated
incubation period
Mean: 6.7 days – –








Backer et al., 2020
(41)
China January 2020 N = 88 cases; Age (lower and





Hu et al., 2020 (42) China January and
February 2020
N = 24 cases; Age [median
(IQR)]: 32.5 (19.0–57.0) years;
Female sex: 77.7%
– Median: 9.5 days
(IQR
3.5–13.0 days)
Li et al., 2020 (26) China January 2020 N = 425 cases; Age [median
(lower and upper limits)]: 59
(15–89) years; Female sex: 49%;
10 cases subsidized the
estimated incubation period, and




– Mean (SD): 7.5(±3.4)
days
(95%CI: 5.3–19 days)
Wu et al., 2020
(43)*
China January 2020 N = 40 cases; 35% of the aged
over 60 years
Median: 6 days – –
Zhang et al., 2020
(44)*
China January 2020 N = 17 cases; Age [median
(lower and upper limits)]: 55





Ki and Task Force
for 2019-nCoV,
2020 (30)
South Korea January and
February 2020
N = 28 cases; Age [median
(lower and upper limits)]: 42








China February 2020 Data from articles and reports:
28 pairs.
– – Median: 4.6 days
(95%CI: 3.5–5.9 days)





N = 778 cases, divided into
elderly group, with 136 cases
and mean age of 68.28 years;
and non-elderly adult group with





Sun et al., 2020
(15)




Jia et al., 2020 (47) China Between January
and February 2020
N = 44 cases; Age [median
(lower and upper limits)]: 46 (1
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TABLE 5 | Continued
Author, year
[references]
Country Study date Characteristics of the sample




Du et al., 2020 (31) China Between January
and February 2020
N = 468 cases – – Mean: 3.96 (95%CI:
3.53–4.39 days)
SD ± 4.75 days
(95%CI:
4.46–5.07 days)





N = 1,590 hospitalized patients;
Mean age: 48.9 (SD ± 16.3)
years; Female sex: 42.7%
Mean: 3.6 days
(SD ± 4.2 days)
– –
Jin et al., 2020 (49) China Between January
and February 2020
N = 651, divided into group with
gastrointestinal symptoms (GI) (N
= 21), Age [mean (SD)]: 46.14 ±
14.19 years; Female sex: 50%;
and asymptomatic group GI (N
= 577), Age [mean (SD)]: 45.09
± 14.45 years; Female sex:
49.05%
With GI symptoms: median:
4 days
(IQR: 3–7 days).








N = 8 children; Age (lower and
upper limits): 2 months to 15
years; Female sex: 25%
Range: 5–10 days – –
Guan et al., 2020
(51)
China Up to January
2020
N = 1,099; Age (median): 47





N: total number of participants in the study.
GI: gastrointestinal symptoms.
95%CI: 95% confidence interval.
IQR: Interquartile range.
SD: Standard deviation.
*Article in Chinese, only the abstract in English was assessed.
from these regions will be increasingly frequent in the literature,
allowing for a more in-depth analysis of other contexts.
One of the parameters most affected by the local context is
the reproduction number (R). Cultural habits, control measures
in place—such as contact tracing, lockdown or border closures—
and the stage of the disease in the territory will directly impact the
value and evolution of R (80). Also, limitations concerning data
quality and the number of observations have been reported in
many studies and may impact estimates. In this sense, we found
three outliers in this review. The one with the lowest R (0.48)
was developed in South Korea (30) using massive testing, contact
tracing and quarantine strategies, in addition to case isolation
(81). One of the highest R values (more than 14) was from data
on a cruise-ship [i.e., an enclosed population for which, although
some restrictive measures were put in place, social distancing was
not possible (22, 23)].
Therefore, for construction of predictive models, in order to
use the most appropriate R value, it is imperative to understand
health systems and their surveillance strategies, as well as
consider the social, economic, demographic and cultural contexts
of the population for which the estimates are made. It is also
worth mentioning that some studies (18, 20, 21, 28, 34) showed a
lower R value after restrictive measures were implemented.
The incubation period, infectious period and serial interval are
also crucial for understanding the evolution of epidemics. In this
regard, there was no wide variation in the incubation period and
serial interval among the selected studies, which may contribute
to the accuracy of predictive models, however, these results must
be consistently confirmed outside of Asia. The scarcity of studies
on the transmissible period is another important aspect, and
there is a need for new studies estimating this parameter for
different populations.
The parameters were mostly extracted for adult, male subjects.
Studies suggest that children develop mild symptoms or remain
asymptomatic, which hinders case identification, however they
play a crucial role in the disease transmission cycle (82). Also,
the predominance of males can be explained due to the larger
proportion of males in the Chinese population (83). Work
conditions of males may also put them at higher risk of exposure
to the pathogen, and some health conditions may increase the
risk of severe disease (84).
The parameters pertaining to the rate of critical cases among
all COVID-19 cases are extremely relevant for managers to
anticipate and put in place the logistics and technologies required
for critical patient care. Due to the different criteria adopted to
define critical cases, it was difficult to establish a homogeneous
classification. However, we identified different situations that led
to cases being classified as critical, allowing for application of
the parameter in predictive models based on the local context
or demand. As for the proportion of deaths among critical cases,
we also found heterogeneity in the studies. We believe that the
criteria used to classify cases as critical may have influenced the
way the fatality rate was presented in this clinical classification,
leading to inconsistent results.
Variability in case classification is a difficulty in several
diseases (85). This heterogeneity is an obstacle in literature





































TABLE 6 | Presentation of parameters: detected cases, critical cases among hospitalized patients, deaths among the critical cases, hospitalization period, and hospitalization period before ARDS or ICU.
Author, year
[references]
Country Study date Characteristics of the sample













before ARDS OR ICU
(N)—mean/median
R. Li et al., 2020
(52)
China March 2020 No information ?/? (14%; 95%CI:
10–18%)a







China February 2020 N = 672 cases; 86.6% aged between
30 and 79 years
44,672 /72,314
(61.8%)
– - – -
Zheng et al., 2020
(54)
China February 2020 N = 25 cases; Age [median (IQR;
range)]: 3 years (2–9 years; 3
months−14 years); Female sex: 44%
– 2b/25 (8%) – – –




N = 112 cases; adults with
cardiovascular disease, age (mean):
62 years; Female sex: 52.67%
– 16c/ 112 (14.28%) – – –





N = 137 hospitalized patients; Age
[median (lower and upper limits)]: 57
(20–83) years: Female sex: 55.47%
– 119b/137 (86.9%) 16/137 (11.7%) – (137)—Median of 7
days, ranging from 1 to
20 days – ARDSg




N = 138 hospitalized patients; Age
[median (IQR; lower and upper limits)]:
56 (42–68; 22–92) years: Female sex:
45, 7%
– 36c/138 (26.1%) 6/36 (16.66%) (47)—Median (among those
who were discharged): 10
days (IQR 7–14 days)
(138)—Median: 5 days
(IQR 1-10 days)g
median of 1 day (IQR 0
– 3 days)c
Cheng et al., 2020
(58)*
China Up to February
2020
N = 1,079 cases; Age [mean (±SD)]:
46 (24) years: Female sex: 46, 8%
– 72d/ 1265 (5.7%) – – –
Guan et al., 2020
(51)
China Up to January
2020.
N = 1,099 cases; Age (median): 47
(IQR 35–58) years; Female sex:
41.9%
– 67c/1,099 (0.06%) 15/173 (8.67%) Median of 13 (IQR
11.5–17.0 days)
Median of 5 days (IQR
2–7 days) between
onset of symptoms and
onset of pneumonia




N = 155 hospitalized patients; Age
[median (IQR)]: 54 (42–66) years;
Female sex: 44.50%
– 37e/ 155 (23.9%) – (22)—Median of fatal cases:




Zhou et al., 2020
(60)
China Up to January
2020
N = 191 hospitalized patients; Age
[median (IQR)]: 56 (46–67) years;
Female sex: 38%
– 53e/191 (28%) 42/53 (78%) (191)—median: 11 days
(IQR: 7–14 days)k;











N = 137 hospitalized patients; Age
[median (IQR)]: 47 (36–55) years;
Female sex: 46.70%




























































































TABLE 6 | Continued
Author, year
[references]
Country Study date Characteristics of the sample













before ARDS OR ICU
(N)—mean/median





N = 41 hospitalized patients; Age
[median (IQR)]: 49 (41–58) years;
Female sex: 27%
– 13c/41 (31.7%) 5/13c (38%) – (12) Median between 8
and 14 daysg




N = 55 asymptomatic cases; Age
[median (lower and upper limits)]: 49
(2–69) years; Female sex: 60%
– 2f/55 (3.6%) – - –




N = 18 cases in isolation at hospital;
Age [median (lower and upper limits)]:
47 (3–73) years; Female sex: 50%
– 2e/18 (11%) – – (18) Mean – 8 daysc
Chen et al., 2020
(65)
China January 2020 N = 99 cases; Age [mean (±SD)]: 55
(13.1) years; Female sex: 32%
– 17g/99 (17%) 11/17 (64.7%) – –





N = 201 hospitalized patients; Age
[median (IQR)]: 51 (43–60) years;
Female sex: 36.30%




He et al., 2020
(67)*
China February 2020 N = 54 hospitalized patients (severe
and critical); Age (mean): 68 years;
Female sex: 37.0%
– – 26/54 (48.1%) – –




N = 80 cases; Age [median (IQR)]:
46.1 (30.7–61.5) years; Female sex:
51.25%
– – – (21)—mean of patients who
were discharged after 8
days
-




N = 8 cases (children); Age (lower
and upper limits): 2 months to 15
years; Female sex: 25%
– 3e/8c (37.5%) – (5 severe/critical patients):
mean of 18.2 days (SD:
4.02 days)
–




N = 15 cases; Age [mean (±SD)
(lower and upper limits)]: 32 (5;
23–40) years; Female sex: 100% (all
pregnant women)
– (2)—mean: 16 days –




N = 199 hospitalized patients; Age
[median (IQR)]: 58 (49–68) years;
Female sex: 39.70%
– 61b/199 (30.65%) – (199)—Median: 15 days
(IQR: 12–17 days)—(with
pneumonia)
Median: 10 days (IQR: 5–14
days) at ICU
-





N = 88 cases; Age [median (IQR)]:
56.7 (43.4–66.8) years; Female sex:
51.60%
– 970e/32,325 (3%) – – –




N = 73 hospitalized patients; Age
[mean (±SD)]: 41.6 (14.5) years;
Female sex: 43.84%
– 3e/73 (4%) – – –




N = 135 cases; Age [mean (±SD)]:
48.87 (17.12) years; Female sex:
48.06%



























































































TABLE 6 | Continued
Author, year
[references]
Country Study date Characteristics of the sample

















France April 2020 N = 124 hospitalized patients at ICU;
Age [median (IQR)]: 60 (51–70) years;
Female sex: 27%
– 85h/ 124c (68.6%) 18/78c (23%) Time to mechanical
ventilation (n = 85): 62
cases upon admission;
13 cases at day 1; 4
cases at day 2; and 6
cases within 7 daysc.




N = 778 cases, divided into elderly
group, with 136 cases and mean age
of 68.28 years; and non-elderly adult
group with 652 cases and mean age
of 41.15 years.
















N = 56 hospitalized patient, divided
into group ≥60 years (N = 18), Age
[median (IQR)]: 68 (65.25–69.75)
years, female sex: 50%; and group <
60 years (N = 38), age [median (IQR)]:
47 (35.75–51.25) years; female sex:
33.337% (group < 60 years)
– 4k/18 (22.22%)
(group ≥ 60) and
2k/38 (5.26%)
(group < 60 years)
– – –




N = 575 hospitalized patients; Age




50/1590 (6.2%) – –
Petrie, 2020 (76) Australia Between January
and February 2020
N = 6,606 cases; Age [median (IQR)]:











N = 298 cases; Age [median (IQR)]:
47 (33-61) years; Female sex: 51.34%







N = 24 critical cases; Age [mean
(±SD)]: 64 (18) years; Female sex:
38%
– – 12/24c (50%) (24)—Median: 12 days (IQR:
8–12 days) at hospital; at
ICU: 9 days (IQR: 4–14
days)
Among survivors: (12) 17
days (IQR: 16–23 days) at
hospital; at ICU (survivors):




























































































TABLE 6 | Continued
Author, year
[references]
Country Study date Characteristics of the sample













before ARDS OR ICU
(N)—mean/median
– – Duration of mechanical
ventilation: general 10 days
(IQR: 7–12 days); among
those who were extubated
(n = 6/18, 33%) 11 days
(IQR: 4–17 days)
–
Jin et al., 2020 (49) China Between January
and February 2020
N = 651, divided into group with
gastrointestinal symptoms (GI) (N =
21), Age [mean (SD)]: 46.14 ± 14.19
years; Female sex: 50%; and
asymptomatic group GI (N = 577),
Age [mean (SD)]: 45.09 ± 14.45


















N = 94,635; Sex female: 62% 4,212/94,635
(4.45%)
– – – –
aThe proportion of registry of infections at the first moment was estimated at 0.65 (95%CI: 0.60–0.69), that is, 65% of infections were registered/detected, in period 1. This proportion dropped to 14% before travel restrictions and was
kept as such throughout the period 2.
bCases who required mechanical ventilation.
cCases who required admission to intensive care unit (ICU).
dCases reported as critical, with no mentioning of case definition.
eCases who presented shock or who required mechanical ventilation or admission to intensive care unit (ICU).
fCases of severe respiratory failure, but with no need for monitoring at intensive care unit (ICU).
gCases who developed acute respiratory distress syndrome.
hCritical cases were defined according to WHO guidelines.
iCases who presented shock.
jCases who had liver injury.
kCases with pneumonia severity index (PSI) 4 and 5.
ARDS, Acute respiratory distress syndrome; ICU, Intensive care unit; GI, gastrointestinal; 95%CI, 95% confidence interval; IQR, Interquartile range; SD, Standard deviation.
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reviews and other epidemiological studies, since it precludes
head-to-head comparison of research studies. In that sense, we
recommend that researchers use a standard classification, based
on a protocol such as that of the WHO (86), to standardize case
presentation and facilitate data use by other groups.We highlight
that in this review, we presented the different classifications of
critical cases, allowing modelers and decision-makers to identify
parameters according to the context.
The length of hospital stays identified in the studies ranged
from one to nearly 3 weeks, and the length of outpatient
stay until ARDS onset or ICU admission ranged from
immediate up to 2 weeks. This information is relevant so
that mathematical models can anticipate the demand for
hospital beds, estimated costs and even potential complications
arising from long stays, supporting decision-making
by managers.
Although the usual method employed in systematic literature
reviews is the gold standard (87), particularly due to its
minimizing of the risk of bias and ensuring critical and
adequate data review, it is time-consuming (88) and usually
takes between 6 months and 2 years for completion (89), which
limits its use in the current emergency context. By simplifying
or omitting components usually included in systematic reviews,
rapid literature reviews can be produced faster, although with a
higher risk of bias (90).
Thus, this protocol was considered a rapid review because,
among the limitations, we highlight the inclusion of only
two databases, the language restriction, the non-paired data
selection and extraction processes, as well as the absence
of a careful evidence quality assessment (90). However,
to reduce these limitations, we used sensitive syntaxes in
comprehensive databases; all review stages were supervised
by experienced researchers with an epidemiology background;
meetings were held to standardize concepts and organize the
execution of all steps. Also, most parameters were extracted
from descriptive observational studies, including cohort
studies and case series, using similar methods, leading
to relative homogeneity in respect to evidence quality.
Furthermore, in terms of limitations, we included studies
with different populations—groups restricted to enclosed
spaces such as cruise-ships, hospitalized patients and specific
professionals, for example—and reviewed data collected
using primary and secondary instruments. However, study
characteristics are presented in all extraction charts, to make for
easier reading.
It should also be noted that some parameters for monitoring
the disease progress were not included. These parameters,
such as 7-days, or 14-days averages of cases and deaths
can be important for health authorities that are using
the mathematical models to make decisions regarding the
reopening of various societal sectors. However, this rapid
review explored the parameters requested by the group
of Brazilian mathematical modelers to determine assistance
measures, and these parameters, at that time, were not
demanded. When replicating this method, the syntax can
be easily adapted to obtain these and other parameters,
as needed.
Due to the difficulties to define good parameters, we
recommend that, when using the data presented in this article,
researchers pay attention to disease transmission chains; the
contribution of different age ranges to infection strength; the
stage of implementation of control measures; and the current
and projected health situation in each territory. Modelers
must also consider the accuracy of results, assess the number
of studies selected, and test uncertainties. We recommend
the use of the syntaxes developed and presented in this
article when performing new searches to update parameters,
contemplating studies conducted in other contexts of time,
place, and people, when needed. Also, we believe that these
syntaxes can be adapted according to the types of models
that are being constructed (e.g., microsimulations, agent-
based modeling, systems dynamic modeling, causal inference
analysis, economic analysis and other epidemiological and
mathematical models) and how impact outcomes are being
looked at/predicted.
Knowing the parameters that help understand the
dynamics of the SARS-CoV-2 pandemic, such as those
presented in this study, allows for modeling of the impact
of surveillance and control measures on virus transmission.
Mathematical models of transmission estimate the number
of infections over time and their consequences, allow
for sizing of the resources needed for patient care,
and assessment of the impact of non-pharmaceutical
interventions (91), supporting decision-making and public
policy management.
The rapid literature review methodology used in this study
was developed and operationalized in slightly more than 1
month, and showed that it is feasible to rapidly identify and
summarize a set of epidemiological parameters in the context of
public health emergencies, where an expressive and increasing
number of publications can be found. The epidemiological
parameters presented here describe information from different
scenarios of COVID-19 transmission, disease and deaths and
may be used to support predictive models used to estimate the
societal impact of the disease, helping decision-makers develop
evidence-based preventive measures and ensure preparedness of
health systems.
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